REG - RTW Biotech Opp. - CORXEL Announces Acceptance of NDA for Aficamten

RTW Biotech OpportunitiesAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO3148Ma&default-theme=true

RNS Number : 3148M  RTW Biotech Opportunities Ltd  15 November 2024

LEI: 549300Q7EXQQH6KF7Z84

15 November 2024

RTW Biotech Opportunities Ltd

CORXEL Announces Acceptance of NDA for Aficamten

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to note the
announcement by portfolio company, CORXEL Pharmaceuticals ("CORXEL"), of the
acceptance by China's National Medical Products Administration (NMPA) of the
New Drug Application (NDA) for Aficamten for the treatment of obstructive
hypertrophic cardiomyopathy (HCM).

Aficamten is an investigational, next-in-class selective small molecule
cardiac myosin inhibitor. It received Breakthrough Therapy Designation for the
treatment of symptomatic obstructive HCM from the U.S. Food & Drug
Administration (FDA) as well as the NMPA. HCM is a genetic heart disease in
which the heart muscle becomes abnormally thick and ultimately limits the
heart's pumping function. It is the most common inherited cardiovascular
disorder, with approximately 132,000-330,000 patients diagnosed in China and
an estimated 748,000-1,870,000 who remain undiagnosed.

 

CORXEL, formerly called Ji Xing Pharmaceuticals, is a leading biotech company
committed to bringing innovative science and medicines to underserved patients
with cardiometabolic diseases. CORXEL was founded and launched by RTW
Investments (the "Investment Manager") in 2019. In July 2020, CORXEL entered
into a license and collaboration agreement with Cytokinetics, a late-stage
biopharmaceutical company headquartered in California, pursuant to which
Cytokinetics granted CORXEL an exclusive license to develop and commercialise
Aficamten in Greater China.

 

Roderick Wong, Managing Partner and CIO at the Investment Manager commented on
the news, "We are thrilled to see the acceptance of the NDA for Aficamten, a
significant milestone for CORXEL and a testament to its commitment to bringing
innovative therapies to patients with cardiometabolic diseases. This
achievement underscores the dedication and hard work of the CORXEL team. We
look forward to continuing to support them in their efforts to deliver
groundbreaking treatments that address unmet medical needs and improve patient
outcomes."

The full text of the announcement can be accessed here
(https://www.corxelbio.com/en/media/corxel-announces-nmpa-acceptance-of-new-drug-application-for-aficamten/)
.

 For Further Information

 RTW Investments, LP                                                        +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development                    biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Cadarn Capital (PR & Communications / Distribution & IR Partner)

                                                                            +44 79 8418 4461

 Lucy Clark (PR)                                                            Lucy@cadarncapital.com (mailto:Lucy@cadarncapital.com)

                                                                            +44 73 6888 3211

 David Harris (Distribution)                                                david@cadarncapital.com

 Deutsche Numis (Joint Corporate Broker)                                    +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities (Joint Corporate Broker)                                   +44 20 7628 1000

 Edward Peel

 Alex Penney

 Elysium Fund Management Limited                                             +44 14 8170 3100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                                       +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFIELFLSLIS